I think I first learned about the link in early 2008.  Nice to see the FDA taking an interest.

WASHINGTON, Nov 17 (Reuters) – Some contrast agents used with magnetic resonance imaging scans appear to carry a higher risk of a potentially fatal skin disease than others, U.S. drug reviewers said in documents released on Tuesday.

The Food and Drug Administration said a staff review found the highest risk of the skin disease, nephrogenic systemic fibrosis (NSF), was associated with GE Healthcare’s (GE.N) Omniscan, Bayer AG’s (BAYGn.DE) Magnevist and Covidien’s (COV.N) Optimark.

Source: UPDATE 2-US FDA sees varying risk from MRI agents | Reuters